GH vs GRAL: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GH and GRAL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GH and GRAL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Guardant Health is a precision-oncology company that reads cancer signals from blood and tissue samples. Its business runs across three lines. Oncology, the largest, sells tests like Guardant360 (comprehensive genomic profiling that helps match patients to targeted therapies) and Guardant Reveal (a blood test for minimal residual disease, meaning traces of cancer left after treatment). Biopharma and Data sells testing, companion-diagnostic development, and real-world data to drugmakers. Screening is the newest and most-watched line: Shield is the first blood test to win full FDA approval as a primary screening option for colorectal cancer in average-risk adults 45 and older. In Q1 2026 the company reported ~$302 million in revenue, with oncology up 36% to ~$205 million on ~86,000 tests, biopharma and data at ~$53 million, and screening at ~$41.6 million on ~44,000 Shield tests (versus ~$5.7 million a year earlier).

Full GH guide

GRAIL, Inc. develops and sells the Galleri multi-cancer early detection (MCED) test, a blood draw that looks for DNA shed by tumors to screen for dozens of cancer types, including many (pancreatic, ovarian, esophageal, liver) that have no standard screening today. The company was originally incubated inside Illumina and became an independent public company after a court-ordered spin-off in 2024, and it now trades on Nasdaq under GRAL. Galleri is sold largely out-of-pocket and through employer and health-system channels while GRAIL pursues regulatory approval and broad insurance reimbursement.

Full GRAL guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GH drivers: Shield colorectal screening ramp; Core oncology growth and leverage.
• GRAL drivers: Galleri volume and revenue growth; FDA approval pathway.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Guardant is unprofitable and cash-consumptive, so it depends on the Shield launch converting into durable, reimbursed volume rather than one-off wins. For GRAL, gRAIL is unprofitable, posting a net loss of roughly $93 million in Q1 2026 and a trailing-twelve-month loss near $395 million, so it depends on its cash balance and eventual funding rather than current earnings.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GH if you believe its drivers more; GRAL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GH and GRAL guides.

GH. Figures are approximate and tied to the asOf date; verify live numbers before acting. GH trades on a high price-to-sales multiple typical of a fast-growing, pre-profit diagnostics company, so the valuation is driven by expected future growth rather than current earnings. The share price is volatile and moved sharply in mid-2026 on reimbursement news (including a July 2026 UnitedHealth coverage decision for Shield), which is why the timeline to 2027 cash-flow breakeven and the pace of Shield adoption matter more than any single quarter.

GRAL. GRAIL trades on revenue growth and its cash runway rather than earnings, since it is deeply unprofitable while it scales Galleri. The roughly $823 million cash position against a trailing operating cash burn near $290 million a year implies a multi-year runway before any need to raise capital. The high price-to-sales multiple reflects investor expectations tied to FDA approval and future reimbursement, not present profitability.

Headline figures (approximate, July 2026): GH shows revenue (q1 2026 quarterly) ~$302 million, up 48% year over year, 2026 revenue guidance (full year) ~$1.30 to $1.32 billion (~32 to 34% growth), adjusted ebitda (q1 2026) ~-$59 million loss (still unprofitable), cash and equivalents ~$1.2 billion at quarter end; GRAL shows revenue (ttm) ~$156M, q1 2026 revenue (yoy) ~$40.8M (+28%), net loss (ttm) ~-$395M, cash & short-term investments ~$823M.

GH and GRAL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GH and GRAL exposure against your real portfolio. It is not an investment adviser.